CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies

Antibody-dependent cell-mediated cytotoxicity (ADCC), which is largely mediated by natural killer (NK) cells, is thought to play an important role in the efficacy of rituximab, an anti-CD20 monoclonal antibody (mAb) used to treat patients with B-cell lymphomas. CD137 is a costimulatory molecule expr...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Kohrt, Holbrook E., Houot, Roch, Goldstein, Matthew J., Weiskopf, Kipp, Alizadeh, Ash A., Brody, Josh, Müller, Antonia, Pachynski, Russell, Czerwinski, Debra, Coutre, Steven, Chao, Mark P., Chen, Lieping, Tedder, Thomas F., Levy, Ronald
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2011
Gaiak:
Lymphoid Neoplasia
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3062409/
https://ncbi.nlm.nih.gov/pubmed/21193697
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-08-301945
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak